Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites

Table 1 Clinical data of patients undergoing laparoscope-assisted CHIPC in gastric cancer complicated by malignant ascites

Case No.	Gender	Age (yr)	Disease course (d)	Ascite volume (mL) [free cancer cells (+/-)]	Diagnosis	Examination	Pathology
1	F	46	17	7000 (+)	GC	GSB	MAC
2	M	58	21	4500 (+)	PGC	PP	M-LDAC
3	F	73	18	6000 (-)	GC	GSB	MDAC
4	F	58	12	4000 (+)	PGC	PP	MAC
5	M	76	7	4800 (+)	PGC	GSB	LDAC
6	M	58	9	9000 (+)	PGC	PP	SRCC
7	F	45	12	7000 (-)	GC	GSB	LDAC
8	F	59	80	4000 (+)	PGC	PP	SRCC
9	M	60	21	4500 (+)	PGC	PP	LDAC
10	M	67	13	4800 (-)	PGC	PP	M-LDAC
11	F	61	15	5000 (+)	GC	GSB	LDAC
12	M	52	14	6000 (+)	PGC	PP	MAC
13	F	68	9	5500 (+)	PGC	PP	LDAC
14	F	45	5	5800 (+)	GC	GSB	SRCC
15	M	59	12	6000 (-)	PG	PP	LDAC
16	F	72	16	7200 (-)	PGC	GSB	M-LDAC

CHIPC: Circulatory hyperthermic intraperitoneal perfusion chemotherapy; GC: Gastric cancer; PGC: Postoperative gastric cancer; GSB: Gastroscopic biopsy; PP: Postoperative pathology; MAC: Mucinous adenocarcinoma; M-LDAC: Medium-low differentiated adenocarcinoma; SRCC: Signet ring cell cancer.

Table 2 Clinical efficacy of laparoscope-assisted CHIPC in patients with gastric cancer complicated by malignant ascites

Case No.	Therapeutic outcome	Port-site seeding (+/-)	KPS mark		Survival time (mo)	Death/living
			Before treatment	After treatment
1	CR	-	40	80	9	Death
2	CR	-	60	90	7	Death
3	CR	-	60	70	5	Death
4	CR	-	50	80	5	Death
5	CR	-	70	90	7	Death
6	CR	-	50	70	4	Death
7	PR	+	40	60	2	Death
8	CR	-	50	70	4	Death
9	CR	-	50	90	5	Death
10	CR	-	60	80	5	Death
11	CR	-	60	80	4	Death
12	PR	+	50	70	3	Death
13	CR	-	40	80	7	Death
14	CR	-	70	80	7	Living
15	CR	-	60	70	4	Living
16	CR	-	60	80	6	Living

KPS: Karnofsky; CR: Complete remission; PR: Partial remission.